Bridgewater Chapter Upcoming Events Join PCCI


IOBiosciences Inc.

Cure liver cancer with engineered allogeneic natural killer cell therapies



Presenter: Sicco H. Popma


Monday, September 17, 2018

Embassy Suites, Chesterbrook, Pennsylvania (directions)




In Q4 2017 IOBio started building laboratory capacity for proof of concept studies in the Philadelphia region, the 6th largest biotech hub in the USA. A core team has been assembled and additional experts will be hired to further develop the technology and generate a clinical Phase 1 asset in three years. A clinical Phase II should be completed by Year 5 at which point a development partner will be sought.


The $1.6 million seed round closed Q2 2018 with private and VC funding from BioAdvance. Next round of fund raising activities started Q3 2018 and is scheduled to close Q2, 2019


Immune oncology Biosciences (IOBiosciences) will generate gene modified cell therapies targeting liver cancer. IOBiosciences will take advantage of three unique technologies ; an unlimited allogeneic cell source, precision gene editing and Boolean constructs. These three elements allow IOBiosciences to lower cost of goods, increase safety and kill targeted tumors with precision. Natural killer cells will be generated from our proprietary, pre-engineered and an ethical pluripotent stem cell source. The NK cells can be further engineered to express multiple targeting and regulating elements allowing the NK cell to kill tumor cells with precision and control. IOBiosciences will focus on liver cancer treatments addressing a high unmet need worldwide.



3 Major Issues


  1. IO Biosciences closed its seed round in May 2018 and is pursuing the next round to fund the company’s expansion, preclinical development, IND filing, and a phase 1 study. Should we try to raise all money for the next three years all at once ($40M, 2Q19) or in steps?
  2. Currently we have one asset. At what point should we spend resources generating a second asset or a portfolio?
  3. We plan to enter the Asian market first (China) via clinical studies and then bring the asset into the USA market. What are the main drawbacks and upsides with this approach? 





6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Sicco Popma, IOBio’s President and Co-founder, will deliver "Elevator" Pitch to the Group

8:20 - A Panel will address three major issues crucial to helping the Company reach the next level.

9:00 - Open discussion: members and guests




Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.



None available at this time


None available at this time


None available at this time


Most PCCI meetings are webcast. To view and participate in the live webcast, login at 7:45 pm . The session begins at 8:00 pm. The URL is:


In addition, the webcast recording of the PCCI meeting will be posted on the PCCI website about two days after the event.

Contact Info:



Our Sponsors

EisnerAmperGlaxoSmithKlineKEH Insurance Agency
New Jersey Institute of Technology
Science CenterWhite and Williams


<Top of the page>





Questions or Coments?

Contact: Peter van der Kam, | (610) 296-8086




Good Company! Good Drink! Good Food! Good Program! Good Fun!


Site Navigation



Pharmaceutical Consulting Consortium International, Inc., or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2018



Tat Communication Inc